Investigators
Veronika Zarnitsyna, Jacob Kohlmeier
1. Define context(s)
reveal new biological insights
other
Primary goal of the model/tool/database
The primary goal is to model how prior T-cell immunity (from infections and vaccinations) affects the dynamics of infection and transmission following exposure to drifted and shifted influenza strains using a multi-scale modeling approach. Animal and human studies showed that T cells can provide strain-transcending protection, resulting in more rapid viral clearance, decreased immunopathology, and improved clinical outcomes, and thus the improvement of strategies to induce protective levels of influenza-specific T cells are of critical importance. We estimate waning of T cell immunity in a mouse model, and how it affects the protection to new strains of influenza. We also explore how the antigenic distance from prior immunity for the live-attenuated influenza vaccine affects generation of optimal protective immunity. Mice studies will inform how to better interpret the limited information about immunity waning available in human studies. Using multi-scale modeling approach we explore how waning of immunity affects the influenza epidemic size and severity. The knowledge gained form this study will help guide future vaccination efforts against influenza viruses to better generate broadly protective T cell immunity within individuals and across the population.
Biological domain of the model
Immunology and epidemiology
Structure(s) of interest in the model
Respiratory system (lungs) and immune system (lymph nodes)
Spatial scales included in the model
Cell level to population level
Time scales included in the model
Hours, months
Other uses for the model (optional)
This model can be generalized to other diseases and/or locations in the body with simple parameter changes.
2. Data for building and validating the model
| Data for building the model |
Published? |
Private? |
How is credibility checked? |
Current Conformance Level / Target Conformance Level |
| in vitro (primary cells cell, lines, etc.) |
On BioRxiv |
|
In progress peer review |
Extensive |
| ex vivo (excised tissues) |
|
|
|
|
| in vivo pre-clinical (lower-level organism or small animal) |
On BioRxiv |
|
In progress peer review |
Extensive |
| in vivo pre-clinical (large animal) |
|
|
|
|
| Human subjects/clinical |
|
|
|
|
| Other: ________________________ |
IEDB, NMDP (published online databases) |
|
replicated experiments |
Extensive |
| Data for validating the model |
Published? |
Private? |
How is credibility checked? |
Current Conformance Level / Target Conformance Level |
| in vitro (primary cells cell, lines, etc.) |
|
|
|
|
| ex vivo (excised tissues) |
|
|
|
|
| in vivo pre-clinical (lower-level organism or small animal) |
|
In progress |
|
Partial |
| in vivo pre-clinical (large animal) |
|
|
|
|
| Human subjects/clinical |
|
|
|
|
| Other: ________________________ |
|
Simulated data |
|
Partial |
3. Validate within context(s)
|
Who does it? |
When does it happen? |
How is it done? |
Current Conformance Level / Target Conformance Level |
| Verification |
Ph.D. student, postdoc, PI |
Throughout |
Testing of controlled cases with known outcomes |
Adequate |
| Validation |
Ph.D student, postdoc |
As data becomes available |
Model comparison to data |
Adequate |
| Uncertainty quantification |
|
|
|
|
| Sensitivity analysis |
Ph.D, postdoc |
Throughout |
Parameter variation comparisons |
Adequate |
| Other:__________ |
|
|
|
|
| Additional Comments |
|
|
|
|
4. Limitations
| Disclaimer statement (explain key limitations) |
Who needs to know about this disclaimer? |
How is this disclaimer shared with that audience? |
Current Conformance Level / Target Conformance Level |
| No current age specific differences |
Scientific community |
Explicit statement in both code and work |
Adequate |
| Assumed homogeneity in individual parameters |
Scientific community |
Explicit statement in both code and work |
Adequate |
|
|
|
|
|
|
|
|
|
|
|
|
5. Version control
| Current Conformance Level / Target Conformance Level |
| Extensive |
|
Naming Conventions? |
Repository? |
Code Review? |
| individual modeler |
Yes |
Yes |
Yes |
| within the lab |
Yes |
Yes |
Yes |
| collaborators |
|
Yes |
|
6. Documentation
|
Current Conformance Level / Target Conformance Level |
| Code commented? |
Extensive |
| Scope and intended use described? |
Adequate |
| User’s guide? |
Adequate |
| Developer’s guide? |
Partial |
7. Dissemination
| Current Conformance Level / Target Conformance Level |
| Adequate |
| Target Audience(s): |
“Inner circle” |
Scientific community |
Public |
| Simulations |
Dropbox |
In progress, currently under development |
|
| Models |
Dropbox, Github |
In progress, currently under development |
Public Github as available |
| Software |
Dropbox, Github |
In progress, currently under development |
Public Github as available |
| Results |
Dropbox, Github, lab meetings |
Publications, conferences |
Public Github as available |
| Implications of results |
Dropbox, Github, lab meetings |
Publications, conferences |
|
8. Independent reviews
| Current Conformance Level / Target Conformance Level |
| Adequate |
| Reviewer(s) name & affiliation: |
Unknown, blind peer review |
| When was review performed? |
2019, another additional planned review for year 3 |
| How was review performed and outcomes of the review? |
Peer reviewed publication, accepted |
9. Test competing implementations
| Current Conformance Level / Target Conformance Level |
| Adequate |
|
Yes or No (briefly summarize) |
| Were competing implementations tested? |
Yes |
| Did this lead to model refinement or improvement? |
Yes |
11. (optional) Additional information to support items 1-10
Our computational model is still in year two early stage development.